RPRX - Royalty Pharma plc News

JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $62

JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raise

marketbeat.com

Royalty Pharma Q2 Earnings Call Highlights

Royalty Pharma NASDAQ: RPRX raised its 2026 outlook for the second consecutive quarter after reporti

seekingalpha.com

Royalty Pharma plc (RPRX) Q2 2026 Earnings Call Transcript

Royalty Pharma (RPRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Royalty Pharma (RPRX) give a sense of how its business performed in

Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates

Royalty Pharma (RPRX) came out with quarterly earnings of $1.32 per share, beating the Zacks Consens

Royalty Pharma Q2 Adj. EPS $1.32 Beats $1.28 Estimate, Sales $674.000M Miss $693.190M Estimate

Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.32 per share which beat the analyst c

Royalty Pharma reports second quarter 2026 results

Portfolio Receipts growth of 6% to $773 million; Royalty Receipts growth of 14% Net cash provided by

Gear Up for Royalty Pharma (RPRX) Q2 Earnings: Wall Street Estimates for Key Metrics

Beyond analysts' top-and-bottom-line estimates for Royalty Pharma (RPRX), evaluate projections for s

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks E

Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives

NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the ap

AstraZeneca, GameStop, Snap And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

U.S. stock futures higher, AstraZeneca dips on merger talks, Apple down 7.4%, other stocks moving lo

Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnin

defenseworld.net

Bank of New York Mellon Corp Reduces Stock Position in Royalty Pharma PLC $RPRX

Bank of New York Mellon Corp decreased its position in Royalty Pharma PLC (NASDAQ: RPRX) by 2.8% dur

Royalty Pharma acquires royalty interest in AstraZeneca's cliramitug for up to $425 million from Neu

NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that i

Neurimmune Sells Portion Of Its Royalty Interest In Cliramitug To Royalty Pharma For Up To $425M, In

Neurimmune announced today that it has sold a portion of its royalty interest in cliramitug to Royal

defenseworld.net

Royalty Pharma PLC $RPRX Holdings Lowered by AlTi Global Inc.

AlTi Global Inc. trimmed its position in Royalty Pharma PLC (NASDAQ: RPRX) by 50.5% in the first qua

defenseworld.net

Chicago Partners Investment Group LLC Purchases New Position in Royalty Pharma PLC $RPRX

Chicago Partners Investment Group LLC purchased a new stake in Royalty Pharma PLC (NASDAQ: RPRX) in

Royalty Pharma declares third quarter 2026 dividend

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RP

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should c

Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026

NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that i

TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $65

TD Cowen analyst Steve Scala maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the pri

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks E

Why Royalty Pharma (RPRX) Could Beat Earnings Estimates Again

Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right

Are You Looking for a Top Momentum Pick? Why Royalty Pharma (RPRX) is a Great Choice

Does Royalty Pharma (RPRX) have what it takes to be a top stock pick for momentum investors? Let's f

Royalty Pharma PLC (RPRX) Hits Fresh High: Is There Still Room to Run?

Royalty Pharma (RPRX) is at a 52-week high, but can investors hope for more gains in the future? We

Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial

Teva will advance TEV-'408 into a Phase 2b vitiligo study after Phase 1b data showed skin pigmen

Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition

Zymeworks will acquire Theravance Biopharma for $929 million, adding YUPELRI cash flows and expandin

Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $66

Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the

JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $58

JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raise

Earnings Scheduled For May 6, 2026

Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript

Royalty Pharma Q1 Adj. EPS $1.30 Beats $1.21 Estimate, Sales $631.000M Miss $1.235B Estimate

Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.30 per share which beat the analyst c

Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $63

Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and

Royalty Pharma Announces R&D Co-Funding Agreement With Johnson & Johnson For Total Of $500M In 2026

Royalty Pharma plc (NASDAQ:RPRX) today announced a research and development (R&D) co-funding agr

Zymeworks And Royalty Pharma Enter Into $250M Funding From Royalty-backed Note With Repayments Due F

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with rep

Zymeworks Secures $250 Million From Royalty Pharma In Royalty-Backed Deal Tied To Ziihera Sales, Ple

Zymeworks Inc. (NASDAQ:ZYME) and Royalty Pharma plc (NASDAQ:RPRX) today announced an agreement for $

Royalty Pharma Q4 Earnings Report: What Investors Need to Know

Royalty Pharma Q4 Adj. EPS $1.47 Beats $1.33 Estimate, Sales $622.000M Miss $795.915M Estimate

Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.47 per share which beat the analyst c

Earnings Scheduled For February 11, 2026

Royalty Pharma's Earnings: A Preview

Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $50

Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the

Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug

Teva and Royalty Pharma have signed a deal worth up to $500 million to advance TEV-408, a drug being

Royalty Pharma To Reports Business Update On Jan. 13 At 44th Annual J.P. Morgan Healthcare Conferenc

Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including re

Royalty Pharma Raises Quarterly Dividend From $0.22 To $0.235 Per Class A Ordinary Share

Royalty Pharma plc (NASDAQ:RPRX) today announced that its board of directors has declared a dividend

Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock So

Pharmaceuticals giant, Merck & Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer dr

What's Going On With Royalty Pharma Stock Wednesday?

Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfr

Royalty Pharma Acquires The Final Portion Of PTC Therapeutics' Remaining Royalty On Roche's Evrysdi

Royalty Pharma plc (NASDAQ:RPRX) today announced that it has acquired the final portion of PTC Thera

Royalty Pharma Acquires Pre-Existing Royalty Interest In Nuvalent's Neladalkib And Zidesamtinib From

Royalty Pharma plc (NASDAQ:RPRX) today announced that it has acquired a pre-existing royalty interes

TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $45

TD Cowen analyst Steve Scala maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the pri